Press Releases

- 96-week interim results of TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) study show no loss of pulmonary function in people with at least one F508del allele, a first for any CFTR modulator – - Real-world data from people treated with KALYDECO ® (ivacaftor) over approximately 6 years

- First patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 Visit - - 91% decrease in daily insulin requirement and simultaneous robust improvements in glucose control as measured by

BOSTON --(BUSINESS WIRE)--Sep. 13, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Virtual 19 th Annual Global Healthcare Conference on Wednesday, September 15 th , 2021 at 11:00 a.m. ET .

BOSTON --(BUSINESS WIRE)--Aug. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced publication in The   New England Journal of Medicine   (NEJM) of results from a Phase 3 study of TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in people with cystic fibrosis

Vertex to use Arbor’s CRISPR gene-editing technology to enhance efforts in developing novel cell therapies for the treatment of serious diseases CAMBRIDGE, MA – August 24, 2021 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Arbor Biotechnologies (Arbor) today announced a new collaboration

BOSTON --(BUSINESS WIRE)--Aug. 4, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Stuart A. Arbuckle has been appointed as the company’s Executive Vice President, Chief Operating Officer (COO), effective immediately. Mr. Arbuckle has served as Vertex’s Executive Vice

- Product revenues of $1.79 billion , an 18% increase compared to Q2 2020 - - Company raises full-year 2021 guidance for product revenues to $7.2 to $7.4B -   - Phase 3 study of next-in-class triple combination for CF to begin in the second half of 2021; multiple additional clinical milestones

- Phase 2 study met primary endpoint and all secondary endpoints - - Phase 2 data demonstrated that a once-daily triple combination of VX-121/ tezacaftor/VX-561 has potential for enhanced clinical benefit compared to TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) - - Initiation of

- Proof-of-concept study of VX-548 in acute pain following bunionectomy surgery open for enrollment - - Second Phase 2 study of VX-548 in acute pain following abdominoplasty surgery to begin in the coming weeks - BOSTON --(BUSINESS WIRE)--Jul. 19, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq:

BOSTON --(BUSINESS WIRE)--Jul. 16, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second-quarter 2021 financial results on Thursday, July 29, 2021 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m. ET .

- With this reimbursement agreement more than 1,500 patients now have access to a CFTR modulator therapy for the first time - LONDON --(BUSINESS WIRE)--Jun. 28, 2021-- Vertex Pharmaceuticals Incorporated   (Nasdaq: VRTX) today announced a national reimbursement agreement with the French Health

- Reimbursement agreement also includes certain future indication extensions across all Vertex CF medicines - - Approximately 1,400 patients will now have access to a CFTR modulator for the first time - LONDON --(BUSINESS WIRE)--Jun. 25, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)

-Approximately 1,100 F/MF patients now eligible for a CFTR modulator to treat the underlying cause of their disease- BOSTON --(BUSINESS WIRE)--Jun. 18, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced Health Canada has granted Marketing Authorization for TRIKAFTA ®

- Beta thalassemia: All 15 patients were transfusion independent after CTX001 infusion - - Sickle cell disease: All seven patients were free of vaso-occlusive crises after CTX001 infusion - BOSTON & ZUG, Switzerland & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun.

- Treatment with VX-864 led to a statistically significant increase from baseline in plasma functional AAT levels as compared to placebo and was generally well tolerated - - Results provide proof-of-mechanism, although magnitude of treatment effect observed unlikely to translate into substantial

- With this approval approximately 1,500 children with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease for the first time - BOSTON --(BUSINESS WIRE)--Jun. 9, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today

- With this approval approximately 1,500 children with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease for the first time - BOSTON --(BUSINESS WIRE)--Jun. 9, 2021-- First paragraph, third sentence of release should read: An

BOSTON --(BUSINESS WIRE)--May 10, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Bank of America Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 10:15 a.m. ET .

-Product revenues of $1.72 billion , a 14% increase compared to Q1 2020- - Company advancing clinical programs in six additional diseases beyond cystic fibrosis- -Multiple Phase 2 proof-of-concept study results expected in 2021 - BOSTON --(BUSINESS WIRE)--Apr.

- New indication includes people ages 12 years and older who have one copy of the F508del mutation regardless of the other mutation type - - People with gating (F/G) or residual function (F/RF) mutations now eligible for the triple combination therapy - LONDON --(BUSINESS WIRE)--Apr.